Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 2, 2011, Pages 201-210

  Heinzow, Hauke Sebastian ^a   Meister, Tobias ^a   Nass, Dominik ^a   Köhler, Michael ^a   Spieker, Tilmann ^a   Wolters, Heiner ^b   Domschke, Wolfram ^a   Domagk, Dirk ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Bridging therapy; HCC; STACE; transarterial chemoembolization

Indexed keywords

CISPLATIN; CORTICOSTEROID; DOXORUBICIN; IODINATED POPPYSEED OIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SUPRASELECTIVE TRANSARTERIAL CHEMOEMBOLIZATION; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETHIODIZED OIL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR BURDEN;

EID: 79951737113     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.525256     Document Type: Article

References (49)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
2. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1): S87-96. (Pubitemid 39423374)
3. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001;48: 103-9. (Pubitemid 32042649)
4. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28. (Pubitemid 15228292)
5. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009;72(3):505-16.
6. Chaparro M, Gonzalez Moreno L, Trapero-Marugan M, Medina J, Moreno-Otero R. Review article: pharmacological therapy of hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008;28(11-12): 1269-77.
7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9. (Pubitemid 26079803)
8. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002;8:765-74. (Pubitemid 35012284)
9. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6. (Pubitemid 36055342)
10. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70. (Pubitemid 32119037)
11. Jung GE, Encke J, Schmidt J, Rahmel A.Model for end-stage liver disease. New basis of allocation for liver transplantations. Chirurg 2008;79:157-63.
12. Freeman RB Jr. Is waiting time a measure of access to liver transplantation? Is shorter necessarily better? Hepatology 2007;46:602-3. (Pubitemid 47344798)
13. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in120 patients with unresectable hepatoma. Radiology 1983; 148:397-401. (Pubitemid 13073577)
14. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688-701; discussion 701-3.
15. Dharancy S, Boitard J, Decaens T, Sergent G, Boleslawski E, Duvoux C, et al. Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. Liver Transpl 2007;13:665-71. (Pubitemid 46796537)
16. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 2008;14:117-22.
17. Timm S, Sotiropoulos GC, Draier M, Knpffer J, Steger U, Lang H. Selective transarterial chemoembolization of advanced hepatocellular carcinomas: a reasonable palliative option. Transplant Proc 2008;40:3179-81.
18. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009;10:425-34.
19. Oldhafer KJ, Chavan A, Fruhauf NR, Flemming P, Schlitt HJ, Kubicka S, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998;29:953-9. (Pubitemid 28559065)
20. Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridgeto liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006;6: 2644-50. (Pubitemid 44571684)
21. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, et al. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008;8:349.
22. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
23. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-38. (Pubitemid 16038197)
24. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
25. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403. (Pubitemid 32496976)
26. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
27. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502-9; discussion 509-11. (Pubitemid 47312148)
28. Maleux G, van Malenstein H, Vandecaveye V, Heye S, Vaninbroukx J, Nevens F, et al. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis 2009;27:157-63.
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
30. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25. (Pubitemid 44900485)
31. Heresbach D, Raoul JL, Bentue-Ferrer D, Bretagne JF, Van den Driessche J, Gastard J. Chemotherapy combined with Lipiodol. In vitro study of the kinetics of release of adriamycin. Gastroenterol Clin Biol 1989;13:775-8. (Pubitemid 19277788)
32. Sakaguchi H, Uchida H, Nishimura Y, Guo QY, Yoshimura H, Ohishi H. Pharmacokinetic study of adriamycin in the emulsion mixed with lipiodol-difference resulting from composition and methods of preparation, and behavior after mesenteric arterial injection in rat. Gan To Kagaku Ryoho 1991;18:1349-55.
33. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170(3 Pt 1):783-6. (Pubitemid 19062602)
34. Sakamoto I, Aso N, Nagaoki K, Matsuoka Y, Uetani M, Ashizawa, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998;18:605-19. (Pubitemid 128467047)
35. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001;12: 321-6. (Pubitemid 32217030)
36. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheom J, Durand F, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005;11:767-75. (Pubitemid 40975578)
37. Perez Saborido B, Meneu JC, Moreno E, García I, Moreno A, Fundora Y. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg 2005;190:383-7. (Pubitemid 41139290)
38. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9: 557-63. (Pubitemid 36701690)
39. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007;13:272-9. (Pubitemid 46351654)
40. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-83. (Pubitemid 35154015)
41. Llovet JM, Bruix J, Fuster J, Castells A, Garcia- Valdecasas JC, Grande L, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998;27:1572-7. (Pubitemid 28264681)
42. Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int 2010;30:166-74.
43. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
44. Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005;100:2708-16.
45. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11:1086-92. (Pubitemid 41341758)
46. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-81. (Pubitemid 46201723)
47. Lencioni R, Cioni D, Pina CD, Crocetti L. Hepatocellular carcinoma: new options for image-guided ablation. J Hepatobiliary Pancreat Surg 2009; Epub ahead of print.
48. Pérez Saborido B, Loinaz Segurola C, Gimeno Calvo A, Meneu Díaz JC, Abradelo de Usera M, Calvo Pulido J, et al. Liver transplantation for hepatocellular carcinoma: our experience from 1986. Transplant Proc 2003;35:1825-6. (Pubitemid 37093726)
49. Herber S, Schneider J, Brecher B, Höhler T, Thelen M, Otto G, Pitton MB. TACE: therapy of the HCC before liver transplantation experiences. Rofo 2005;177: 681-90. (Pubitemid 40862525)